Meeting
2015 ASCO Annual Meeting
A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (≤ 25).
Authors
Maysa M. Abu-Khalaf
Yale Cancer Center, Yale School of Medicine, New Haven, CT
Maysa M. Abu-Khalaf , Sarah Schellhorn Mougalian , Tara Beth Sanft , Erin Wysong Hofstatter , Gina G. Chung , Kerin B. Adelson , Andrea Silber , Debra S. Brandt , Kathleen E. Bober-Sorcinelli , Neal Fishbach , Wajih Zaheer Kidwai , Kert D. Sabbath , Michael DiGiovanna , William M. Sikov , Lajos Pusztai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT02236572
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS630)
DOI
10.1200/jco.2015.33.15_suppl.tps630
Abstract #
TPS630
Poster Bd #
116b
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial.
First Author: Francesco Perrone
Poster
2016 ASCO Annual Meeting
Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI).
First Author: Mario Campone
Poster
2015 ASCO Annual Meeting
Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006)
First Author: Miguel Martin
Poster
2012 Breast Cancer Symposium
Phase II randomized trial of toremifene 120 mg compared with exemestane 25 mg after prior nonsteroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive breast cancer.
First Author: Hirotaka Iwase